What is Castle Biosciences's operating lease liabilities?

Castle Biosciences (CSTL) reported operating lease liabilities of -$172K in Q1 2026.

How has Castle Biosciences's operating lease liabilities changed year-over-year?

Castle Biosciences's operating lease liabilities increased by 67.3% year-over-year, from -$526K to -$172K.

What is the long-term trend for Castle Biosciences's operating lease liabilities?

Over 3 years (2021 to 2025), Castle Biosciences's operating lease liabilities has grown at a 14.4% compound annual growth rate (CAGR), from -$852K to -$1.28M.

Castle Biosciences CSTL Operating lease liabilities

Operating lease liabilities at other companies

VeracyteVCYT

——

NeoGenomicsNEO

——

Fulgent Genetics, Inc.FLGT

——

BillionToOne, Inc. BLLN

——

Tempus AI, Inc.TEM

——

Aura Biosciences, Inc.AURA

——

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's operating lease liabilities?: Castle Biosciences (CSTL) reported operating lease liabilities of -$172K in Q1 2026.
How has Castle Biosciences's operating lease liabilities changed year-over-year?: Castle Biosciences's operating lease liabilities increased by 67.3% year-over-year, from -$526K to -$172K.
What is the long-term trend for Castle Biosciences's operating lease liabilities?: Over 3 years (2021 to 2025), Castle Biosciences's operating lease liabilities has grown at a 14.4% compound annual growth rate (CAGR), from -$852K to -$1.28M.